297 related articles for article (PubMed ID: 37047188)
21. Simple protocol for measuring CD11b+ GR-1+ (Ly6C+/Ly6G+) myeloid cells from a minimum volume of mouse peripheral blood.
Borgna E; Gamba JC; Prochetto E; Marcipar I; Cabrera G
Methods Cell Biol; 2024; 184():59-68. PubMed ID: 38555158
[TBL] [Abstract][Full Text] [Related]
22. Myeloid-derived suppressor cell functionality and interaction with Leishmania major parasites differ in C57BL/6 and BALB/c mice.
Schmid M; Zimara N; Wege AK; Ritter U
Eur J Immunol; 2014 Nov; 44(11):3295-306. PubMed ID: 25142017
[TBL] [Abstract][Full Text] [Related]
23. CCR5 Directs the Mobilization of CD11b
Hawila E; Razon H; Wildbaum G; Blattner C; Sapir Y; Shaked Y; Umansky V; Karin N
Cell Rep; 2017 Nov; 21(8):2212-2222. PubMed ID: 29166611
[TBL] [Abstract][Full Text] [Related]
24. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.
Binsfeld M; Muller J; Lamour V; De Veirman K; De Raeve H; Bellahcène A; Van Valckenborgh E; Baron F; Beguin Y; Caers J; Heusschen R
Oncotarget; 2016 Jun; 7(25):37931-37943. PubMed ID: 27177328
[TBL] [Abstract][Full Text] [Related]
25. Functional characterization of myeloid-derived suppressor cell subpopulations during the development of experimental arthritis.
Wang W; Jiao Z; Duan T; Liu M; Zhu B; Zhang Y; Xu Q; Wang R; Xiong Y; Xu H; Lu L
Eur J Immunol; 2015 Feb; 45(2):464-73. PubMed ID: 25352399
[TBL] [Abstract][Full Text] [Related]
26. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
[TBL] [Abstract][Full Text] [Related]
27. Temporal and spatial profile of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in ischemic stroke in mice.
Kawano T; Shimamura M; Nakagami H; Kanki H; Sasaki T; Mochizuki H
PLoS One; 2019; 14(5):e0215482. PubMed ID: 31048856
[TBL] [Abstract][Full Text] [Related]
28. Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression.
Patel A; Oba T; Kajihara R; Yokoi T; Abrams SI; Ito F
J Immunol; 2021 Sep; 207(5):1298-1309. PubMed ID: 34362833
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneity of Ly6G
Heim CE; West SC; Ali H; Kielian T
Infect Immun; 2018 Dec; 86(12):. PubMed ID: 30249747
[TBL] [Abstract][Full Text] [Related]
30. Myeloid-derived suppressor cell function is diminished in aspirin-triggered allergic airway hyperresponsiveness in mice.
Shi M; Shi G; Tang J; Kong D; Bao Y; Xiao B; Zuo C; Wang T; Wang Q; Shen Y; Wang H; Funk CD; Zhou J; Yu Y
J Allergy Clin Immunol; 2014 Nov; 134(5):1163-74.e16. PubMed ID: 24948368
[TBL] [Abstract][Full Text] [Related]
31. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.
Movahedi K; Guilliams M; Van den Bossche J; Van den Bergh R; Gysemans C; Beschin A; De Baetselier P; Van Ginderachter JA
Blood; 2008 Apr; 111(8):4233-44. PubMed ID: 18272812
[TBL] [Abstract][Full Text] [Related]
32. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
33. Age-related expansion and increased osteoclastogenic potential of myeloid-derived suppressor cells.
Li Z; Zhao Y; Chen Z; Katz J; Michalek SM; Li Y; Zhang P
Mol Immunol; 2021 Sep; 137():187-200. PubMed ID: 34274794
[TBL] [Abstract][Full Text] [Related]
34. Myeloid-Derived Suppressor Cells in
Fresno M; Gironès N
Front Cell Infect Microbiol; 2021; 11():737364. PubMed ID: 34513737
[TBL] [Abstract][Full Text] [Related]
35. Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer.
Sasidharan Nair V; Saleh R; Toor SM; Taha RZ; Ahmed AA; Kurer MA; Murshed K; Alajez NM; Abu Nada M; Elkord E
Clin Epigenetics; 2020 Jan; 12(1):13. PubMed ID: 31941522
[TBL] [Abstract][Full Text] [Related]
36. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.
Won H; Moreira D; Gao C; Duttagupta P; Zhao X; Manuel E; Diamond D; Yuan YC; Liu Z; Jones J; D'Apuzzo M; Pal S; Kortylewski M
J Leukoc Biol; 2017 Aug; 102(2):423-436. PubMed ID: 28533357
[TBL] [Abstract][Full Text] [Related]
37. ILT3 (LILRB4) Promotes the Immunosuppressive Function of Tumor-Educated Human Monocytic Myeloid-Derived Suppressor Cells.
Singh L; Muise ES; Bhattacharya A; Grein J; Javaid S; Stivers P; Zhang J; Qu Y; Joyce-Shaikh B; Loboda A; Zhang C; Meehl M; Chiang DY; Ranganath SH; Rosenzweig M; Brandish PE
Mol Cancer Res; 2021 Apr; 19(4):702-716. PubMed ID: 33372059
[TBL] [Abstract][Full Text] [Related]
38. [Circulating Myeloid Suppressor Cells and Their Role in Tumour Immunology].
Pilatova K; Budinská E; Bensciková B; Nenutil R; Šefr R; Fedorová L; Hanáková B; Brychtová V; Zdražilová Dubská L
Klin Onkol; 2017; 30(Supplementum1):166-169. PubMed ID: 28471197
[TBL] [Abstract][Full Text] [Related]
39. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.
Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y
Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053
[TBL] [Abstract][Full Text] [Related]
40. Myeloid derived suppressor cells in peripheral blood can be a prognostic factor in canine transitional cell carcinoma.
Yokota S; Yonezawa T; Momoi Y; Maeda S
Vet Immunol Immunopathol; 2024 Mar; 269():110716. PubMed ID: 38308864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
